Cartalax Safety Questions: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or any substance discussed here. It summarises what the published literature reports about the short peptide often called Cartalax, and it states plainly where no data exist.

What Cartalax Is: What Studies Report

Cartalax is the name commonly applied to the synthetic tripeptide AED (alanyl-glutamyl-aspartate), one member of a family of very short peptides developed and studied largely within Russian gerontology and bioregulation research. In that literature the peptide is usually handled as a putative regulator of cell function rather than as a drug candidate with an established toxicology package. Researchers compared AED with the dipeptide KE in human skin fibroblast cultures undergoing replicative ageing and described differences in the functional activity of those cells between the two peptides in a 2020 report in Bulletin of Experimental Biology and Medicine. The broader framework for these peptides was set out in work arguing that short peptides act on gene expression, described in a 2016 paper on short peptides regulating gene expression, and in earlier work on tissue-specific effects of peptides reported in a 2001 Bulletin of Experimental Biology and Medicine article.

That framing matters for any safety question. Studies designed to test whether a molecule changes gene expression in a cultured cell line are not designed to detect organ toxicity, allergic reactions, drug interactions or effects on pregnancy. The absence of reported harm in such papers is not the same as evidence of safety.

Whether Human Safety Trials Exist: What Studies Report

Among the verified literature reviewed for this page, no randomised controlled trial, no phase I tolerability study and no pharmacovigilance report on Cartalax in living human participants was identified. Human material appears in this literature only as isolated cells or tissue cultures. For example, human blood lymphocytes stimulated with phytohaemagglutinin were used to examine telomere length and mitotic index after exposure to the related tetrapeptide AEDG in a 2019 study in Bulletin of Experimental Biology and Medicine, and human oral stem cells were used in a 2020 Stem Cell Reviews and Reports paper on short peptides and ageing of those cells. Cells in a dish cannot report nausea, blood-pressure changes, injection-site reactions or immune responses, and they cannot show what a peptide does after absorption, distribution and elimination in a whole person.

Consequently, the honest answer to "what are the side effects of Cartalax in humans?" is that published human safety data were not located. Any list of side effects circulating outside the peer-reviewed literature is not traceable to the studies summarised here.

Adverse Events in Animal Models: What Studies Report

The animal work in this family of peptides was generally framed around protection or functional restoration rather than around toxicology endpoints. Researchers examined peptides in a model of cisplatin-induced acute renal failure and reported restoration of functional state of the kidneys in a 2015 Bulletin of Experimental Biology and Medicine study, and a related tripeptide, EDL, was studied for a nephroprotective effect in acute kidney injury of different origins in a 2017 report in the same journal. Neither of those reports, within the scope of their indexed abstracts, was structured as a dose-ranging safety or maximum-tolerated-dose study, and neither described a formal adverse-event schedule of the kind used in regulatory toxicology.

In the nervous system, tripeptides described as epigenetic regulators were tested in a mouse model of Alzheimer's disease, where researchers reported neuroprotective effects in a 2021 paper in Pharmaceuticals. Again, the published emphasis was on benefit-type endpoints. Readers looking for organ-by-organ safety data — liver enzymes, haematology panels, histopathology across tissues, reproductive toxicity — will not find those endpoints described in this set of papers.

Doses and Durations: What Studies Report

Specific dosing information for Cartalax in humans was not established in the verified literature reviewed here, and this page therefore states no dose. In cell-culture work, exposure is expressed as a concentration in culture medium rather than as a body-weight dose, and those culture conditions do not translate into a human exposure. The comparison of AED and KE peptides in replicatively ageing human skin fibroblasts reported in the 2020 Bulletin of Experimental Biology and Medicine study was an in-vitro design, as was the earlier examination of peptide regulation of skin fibroblast functions during ageing in vitro described in a 2016 report. Without human pharmacokinetic data — absorption, half-life, clearance route — there is no published basis for converting laboratory concentrations into any exposure in a person.

Mechanism Claims and What They Do Not Cover: What Studies Report

Much of the mechanistic literature on this peptide family concerns gene expression and epigenetic regulation. Short peptides were described as capable of regulating gene expression in a 2016 Bulletin of Experimental Biology and Medicine paper, and epigenetic regulation of adaptogenesis in pathology and ageing was discussed in a 2021 review in Advances in Gerontology. A related peptide-protein complex from cattle sclera was characterised structurally and reported to show chaperone activity in a 2020 paper in Biochemistry and Biophysics Reports.

A mechanism that involves gene expression is, in principle, a reason for more safety scrutiny rather than less: molecules proposed to alter transcriptional programmes raise questions about cell proliferation, differentiation and long-term tissue behaviour that only long-duration in-vivo studies can address. Those long-duration studies were not present in the verified set. The broader peptide literature makes the same point indirectly — an overview of the pineal tetrapeptide Epitalon summarised a range of reported bioactivity and noted its promising properties in a 2025 review in the International Journal of Molecular Sciences, which is a description of research interest rather than of established human safety.

Contraindications, Interactions and Special Populations: What Studies Report

No contraindication list, no drug-interaction study and no data in pregnancy, lactation, paediatric populations, renal impairment or hepatic impairment for Cartalax were identified in the verified literature. The kidney studies in this family examined peptides in models of chemically induced injury, as in the 2015 cisplatin-induced acute renal failure report and the 2017 EDL nephroprotection report, but injury-model research does not answer whether a peptide is safe in people with existing kidney disease. Where a page like this cannot cite a study, the correct statement is that the data do not exist, not that the compound is safe.

Study Landscape at a Glance

How This Literature Should Be Read

Several features of the published record limit how far any safety conclusion can travel:

• Concentration in one research tradition. A large share of the reports, including the 2001 tissue-specific effects paper and the 2016 fibroblast ageing paper, appeared in the same journal family, and independent replication outside that tradition is limited.
• In-vitro dominance. Culture systems, including the human stem cell work in the 2020 Stem Cell Reviews and Reports study, cannot detect systemic toxicity.
• Peptide substitution. Findings for AEDG, EDL or peptide-protein complexes, such as the chaperone activity reported in the 2020 sclera complex paper, are frequently repeated online as though they described Cartalax. Each sequence is a distinct molecule.
• Short observation windows. None of the verified reports described long-term follow-up in a living human.

Open Questions the Literature Has Not Answered

1. What happens to AED after administration in humans — how it is absorbed, distributed, metabolised and cleared.
2. Whether any dose level produces adverse effects in animals under formal toxicology protocols.
3. Whether the gene-expression effects described in the 2016 short-peptide paper persist, reverse or accumulate over long exposure.
4. Whether immune responses, including antibody formation against a synthetic peptide, occur in people.
5. Whether findings in injury models, such as the 2015 kidney study, have any bearing on healthy physiology.

Regulatory Context

Cartalax is not an approved medicine in the United States, the European Union or the United Kingdom, and material of this kind is generally labelled for research use only. Research-use-only labelling means a substance has not been reviewed for human safety or efficacy by a medicines regulator, and it is a statement about legal status rather than about biological risk. Discussion of regulatory status here is descriptive and is not legal advice.

Summary of the Safety Picture

The published record on Cartalax describes a short peptide investigated chiefly for effects on cell ageing and gene expression, with adjacent studies on related peptides in kidney and neurological models. Researchers reported functional and protective findings in those models, as in the 2021 Alzheimer's-model paper and the 2017 kidney paper, but the study designs were not built to characterise harm. No human adverse-event data, contraindication list or interaction profile for Cartalax was identified in the verified literature, and that gap is the single most important fact on this page.

References

• Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging (Bulletin of Experimental Biology and Medicine, 2020)
• Short Peptides Regulate Gene Expression (Bulletin of Experimental Biology and Medicine, 2016)
• Tissue-specific effects of peptides (Bulletin of Experimental Biology and Medicine, 2001)
• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro (Bulletin of Experimental Biology and Medicine, 2016)
• Short Peptides Protect Oral Stem Cells from Ageing (Stem Cell Reviews and Reports, 2020)
• Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Bulletin of Experimental Biology and Medicine, 2019)
• Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure (Bulletin of Experimental Biology and Medicine, 2015)
• Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Bulletin of Experimental Biology and Medicine, 2017)
• Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease (Pharmaceuticals, 2021)
• Epigenetic regulation of adaptogenesis by pathology and aging (Advances in Gerontology, 2021)
• Peptide-protein complex from cattle sclera: Structural aspects and chaperone activity (Biochemistry and Biophysics Reports, 2020)
• Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties (International Journal of Molecular Sciences, 2025)